Chemomab Therapeutics LTD (CMMB) 13F Investor Activity Report (Q2 2026)

CMMB ranks #9446 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CMMB is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

13 institutions disclose a position in CMMB, but none treat it as a major bet — even Philadelphia Investment Partners, LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

Kestra Private Wealth Services, LLC has added to its CMMB position for two straight quarters, increasing it by $14.6K to reach $100.0K today.

XTX Topco Ltd has trimmed its CMMB position for two straight quarters, cutting it by $5.5K while still holding $25.9K.

CMMB reported a net loss of $27.6M in its latest fiscal year.

• Not yet profitable — net loss of $27.6M in the latest fiscal year
• Net income declined year over year, from -$12.5M to -$27.6M
• Operating cash flow was negative, using $20.4M in cash
• Current ratio of 6.18x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.19x equity — within a conventional range